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Immunology
Chlamydia, the leading sexually-transmitted bacterial infection in the United States, 
can cause severe health disorders including 
inflammation of the cervix in women and the 
urethra in men; pelvic inflammatory disease; 
infertility and ectopic pregnancy; trachoma, a 
preventable, blinding disease in underdeveloped 
parts of the world; and an inflammatory reactive 
arthritis.
A Wayne State University husband–wife team is 
leading research to elucidate the molecular details of 
the synovial, or joint-related, pathogenesis process 
elicited by Chlamydia trachomatis, (C trachomatis), 
as well as developing a vaccine to protect against 
infection. 
Alan Hudson, Ph.D. and Judith Whittum-
Hudson, Ph.D., both professors of immunology and 
microbiology in the Wayne State University School 
of Medicine, have discovered that C trachomatis can 
generate persistent, difficult to detect infections of 
the synovium, the thin layer of tissue which lines 
the joint space, causing reactive arthritis. Until 
recently, such persistent infections had proven 
resistant to antibiotics and other relevant therapies. 
“We have discovered that, contrary to current 
thinking, it is not genital strains of C trachomatis 
that cause the inflammatory arthritis,” said Hudson. 
“Rather, only trachoma strains known for causing 
ocular disease, which are found in low numbers 
in genital inocula, appear to disseminate from the 
genital tract to the joint.” 
Further studies in collaboration with a 
rheumatologist/researcher at the University of 
South Florida’s School of Medicine, demonstrated 
for the first time that a combination antibiotic 
treatment, in lieu of single antibiotic treatment, is 
effective in eliminating persistent C trachomatis in 
the synovium. This has implications for treatment 
of disseminated chlamydial infections at other 
anatomic sites in addition to the synovium. 
Taking a combined antimicrobial approach using 
one antibiotic that inhibits RNA polymerase and 
heat shock proteins along with another that inhibits 
bacterial protein synthesis, eradication of persistent 
chlamydiae may lead to improvement or possibly a 
cure for the disease. 
“Our data give hope for the development of 
therapies to improve the clinical symptoms of 
Chlamydia-induced reactive arthritis centered on 
this new treatment approach,” said Hudson. “These 
combined therapies may not only significantly 
improve the treatment of persistent chlamydial 
infections; they may also have important 
implications in a number of other chronic 
Chlamydia-related diseases.”
Getting closer to eliminating Chlamydia
After nearly four decades of research, 
Whittum-Hudson’s research on chlamydial 
immunopathogenesis and vaccine development 
is beginning to pay off. She has developed and 
characterized novel vaccine candidates against 
chlamydial infections, and several patent 
applications have been possible because of these 
efforts.
Most recently Whittum-Hudson has identified 
several peptides that have potential as vaccines 
against Chlamydia. With many areas of the world 
lacking access to basic health care and treatments 
such as antibiotics, a new vaccine given orally or 
through intranasal delivery may offer more effective 
protection against Chlamydia infections, ultimately 
decreasing a significant number of cases of the 
infection.
“I am also exploring novel combinations of 
these and additional peptides that are mimotopes 
for the carbohydrate associated with a chlamydial 
glycolipid antigen,” said Whittum-Hudson.  
“Because these peptides mimic the chlamydial 
organism, they induce antibodies and other 
immune responses that recognize the whole 
organism and may allow them to serve as vaccine 
candidates.” An important aspect of these vaccine 
candidates is that they could protect against all 
types of Chlamydia capable of infecting humans as 
well as many animal species.
Using the same theory as vaccine delivery, 
the duo is also working with researchers from 
WSU’s Department of Chemical Engineering to 
develop nanomedicine approaches to diagnose and 
deliver therapy for Chlamydia-associated diseases, 
particularly in the context of the inflammatory 
reactive arthritis. These collaborations have led to 
new nanomedicine endeavors with nanoparticles 
and dendrimers that specifically target infected 
cells for diagnosis and treatment of chlamydial 
infections. New patent applications and grants have 
resulted from these nanotechnology focused studies. 
“These various research efforts demonstrate an 
ongoing, upward trajectory in new approaches 
to chlamydial research,” said Whittum-Hudson. 
“Through this cutting-edge research, we are 
closer to one day eliminating diseases caused by 
Chlamydia.”
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About Dr. Judith Whittum-Hudson:    
Dr. Whittum-Hudson received a B.A. in biology from Wells College 
and a Ph.D. in pathology from the University of Connecticut. She 
did postdoctoral research training at the University of Texas Health 
Science Center. She joined Wayne State University in 1998. 
To learn more, visit: 
http://www.med.wayne.edu/immunology/pages/Faculty_Web_Pages/whittum-hudson.html
 
About Dr. Alan Hudson:    
Dr. Hudson received a B.A. in biology and chemistry from Hamilton College 
and a Ph.D. in molecular biology from the City University of New York. He did 
postdoctoral research training at the University of Paris and at the University 
of Texas Health Sciences Center at Dallas. He joined Wayne State University 
in 1997.
To learn more, visit: 
http://www.med.wayne.edu/immunology/Pages/Faculty_Web_Pages/hudson.html
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